---
layout: default
title: Antimony Trisulfide Bryonia Alba Root Causticum De
parent: 僅模型預測 (L5)
nav_order: 331
evidence_level: L5
indication_count: 0
---

# Antimony Trisulfide Bryonia Alba Root Causticum De
{: .fs-9 }

證據等級: **L5** | 預測適應症: **0** 個
{: .fs-6 .fw-300 }

---

## 目錄
{: .no_toc .text-delta }

1. TOC
{:toc}

---

<div id="pharmacist">

## 藥師評估報告

</div>

# Multi-Ingredient Homeopathic Formula: From Unspecified Indication — No Repurposing Target Identified

## One-Sentence Summary

This product is a 19-ingredient homeopathic combination formula (including Lycopodium clavatum, Thuja occidentalis, Strychnos nux-vomica, Sepia officinalis, Sulfur, and others) with no registered market approval and no recorded original indication.
The TxGNN model was unable to generate any repurposing predictions for this compound, as the complex multi-ingredient composition cannot be mapped to a DrugBank entry — a prerequisite for knowledge-graph-based analysis.
With zero clinical trials, no supporting literature, and no regulatory approvals identified, the evidence base is currently insufficient to proceed with any evaluation.

---

## Quick Overview

| Item | Content |
|------|---------|
| Original Indication | Not recorded |
| Predicted New Indication | None |
| TxGNN Prediction Score | N/A |
| Evidence Level | L5 — no predictions generated |
| US Market Status | Not marketed |
| Number of NDAs | 0 |
| Recommended Decision | Hold |

---

## Why No Prediction Was Generated

The TxGNN model constructs its predictions by traversing knowledge-graph edges between drug nodes (sourced primarily from DrugBank) and disease nodes. This product — a 19-ingredient homeopathic combination formula — has no DrugBank identifier and no mechanism-of-action data on record. Without a resolvable drug node in the knowledge graph, the model has no starting point from which to compute disease associations, and therefore returns an empty prediction set.

The formula contains ingredients that are classical homeopathic preparations: Graphite, Sulfur, Lycopodium clavatum spore, Sepia officinalis juice, Thuja occidentalis leafy twig, Strychnos nux-vomica seed, Toxicodendron pubescens leaf, Mercuric sulfide, and others. In homeopathic practice these are used at extreme dilutions, which further complicates pharmacological profiling through conventional drug databases. None of the 19 ingredients could be individually linked back to a structured pharmacological record in the current pipeline.

Additionally, because the product has no recorded original indication, the secondary step of assessing mechanistic plausibility between an existing approved use and a novel target cannot be performed. Both input anchors required by the evaluation framework — drug mechanism and baseline clinical use — are absent.

---

## Clinical Trial Evidence

Currently no related clinical trials registered.

---

## Literature Evidence

Currently no related literature available.

---

## US Market Information

This product has no registered NDAs and is not currently marketed in the United States.

---

## Safety Considerations

Formal warning and contraindication data are unavailable from the current query. However, two ingredients in this formula carry non-trivial toxicological concerns even at trace levels and should be explicitly addressed before any clinical development program is initiated:

- **Mercuric sulfide** — a mercury-containing compound; chronic mercury exposure is associated with nephrotoxicity and neurotoxicity.
- **Strychnos nux-vomica seed** — source of strychnine and brucine; therapeutic window is extremely narrow and strychnine poisoning causes convulsions at sub-gram doses.

Any regulatory submission will need to demonstrate that these components are present only at safe (or homeopathically diluted) concentrations, with supporting toxicological justification.

---

## Conclusion and Next Steps

**Decision: Hold**

**Rationale:**
The TxGNN model produced no repurposing predictions because this multi-ingredient homeopathic formula cannot be mapped to a DrugBank node, and no original indication is on record — both of which are prerequisites for meaningful knowledge-graph analysis. There is no clinical or preclinical evidence base to build upon at this stage.

**To proceed, the following is needed:**

- **Resolve drug identity**: Confirm whether this product should be evaluated as a single combined entity or as individual components; obtain or create a DrugBank (or equivalent) mapping for each active ingredient.
- **Document the original indication**: Retrieve the manufacturer's labelled indication from the product insert or regulatory submission.
- **Obtain MOA data**: Query DrugBank, ChEMBL, or primary pharmacology literature for each ingredient.
- **Retrieve safety dossier**: Download the product insert (or TFDA submission records) to extract contraindications, warnings, and drug interaction data — currently a blocking data gap (DG001).
- **Clarify regulatory pathway**: Determine whether this product is governed by homeopathic product regulations or conventional drug regulations, as this affects which evaluation framework applies.
- **Re-run TxGNN pipeline**: Once at least one ingredient has a valid DrugBank mapping, re-submit for knowledge-graph prediction on a per-ingredient basis.
## Disclaimer

This content is for research purposes only and does not constitute medical advice.
Clinical validation is required before any clinical application.

---

